Indian Pharma Experts Expect Boost in Trade with Trump's US Presidency

Indian pharmaceutical experts anticipate positive trade conditions with Donald Trump assuming the presidency of the US. The United States continues to be an important market for Indian pharmaceutical firms, representing roughly 30% of India's overall pharma exports. Specialists indicate that the US is experiencing significant drug shortages, presenting a chance for local pharmaceutical companies to grow and address the gap.

Industry specialists are optimistic about India's path as the US encounters shortages and delays. They mentioned that numerous blockbuster medications will be losing patent protection from 2025 to 2029. They said with many blockbuster drugs were going off-patent between 2025 and 2029. "The Indian pharma industry will have a further growth opportunity in the form of generics."

"The fact that India is among the largest suppliers of generics to some of the countries with strictest regulatory norms and has the largest number of US FDA-approved plants outside of the US is the testament to the country's commitment to fulfilling the global need for life-saving medicines," said Sudharshan Jain, general secretary, Indian Pharmaceutical Alliance (IPA), which represents country's largest drugmakers.

Companies like Sun Pharma, Aurobindo, Dr Reddy's, and Torrent Pharmaceuticals are doing exceedingly well on exports led by the key US market. The formulations business is expected to do well in the US particularly due to backorders. "The demand has increased, and they are filling the void from India," an industry executive said.